Current literature on PBX3 is known to be a functionally significant TF in a range of cancers, including prostate cancer, and linked to shorter overall survival; and the miR inhibitor of PBX3, miR-let-7d, is regulated by androgen (47). Here, TF is linked to prostate carcinoma.